MedTrace Logo

Treatment With Pazopanib for Neoadjuvant Breast Cancer

NCT00849472 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2014-03-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.

Conditions

  • Neoplasms, Breast

Interventions

DRUG

doxorubicin + cyclophosphamide

4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.

DRUG

paclitaxel + pazopanib

4 cycles of paclitaxel + pazopanib

PROCEDURE

surgery

neoadjuvant surgery for breast cancer

DRUG

pazopanib monotherapy

6 months of treatment with pazopanib monotherapy

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-12-31
Completion
2013-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849472 on ClinicalTrials.gov